The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 - Full Text View

Purpose

To evaluate the effects of paricalcitol capsules on cardiac structure and function over 48 weeks in patients with Stage 3/4 chronic kidney disease (CKD) who had left ventricular hypertrophy (LVH).

Condition	Intervention	Phase
Chronic Kidney Disease Left Ventricular Hypertrophy	Drug: paricalcitol Drug: placebo	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
Official Title:	The PRIMO Study: Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4

Resource links provided by NLM:

MedlinePlus related topics: Chronic Kidney Disease

Drug Information available for: Paricalcitol

U.S. FDA Resources

Further study details as provided by AbbVie:

Primary Outcome Measures:

Change From Baseline in Left Ventricular Mass Index (LVMI) Over 48 Weeks Measured by Cardiac Magnetic Resonance Imaging (MRI) [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
The Central Cardiac MRI Core Laboratory (CCL) interpreted and analyzed all cardiac MRI data. Left Ventricular Mass (LVM) was normalized to the participant's height by the following equation to obtain LVMI: LVM (grams) divided by height (meters)^2.7.

Secondary Outcome Measures:

Change in Diastolic Mitral Annular Relaxation Velocity (E') [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
Diastolic mitral annular relaxation velocity (lateral E wave velocity; E') is a measure of diastolic function.
Change in Ratio of Peak E Wave Velocity to Lateral E Wave Velocity (E/E') [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
The ratio of peak E wave velocity to lateral E wave velocity (E/E') is a measure of diastolic function.
Change in E-wave Deceleration Time (DT) [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
E-wave deceleration time (DT) is a measure of diastolic function.
Change in Isovolumetric Relaxation Time (IVRT) [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
Isovolumetric relaxation time (IVRT) is a measure of diastolic function.
Change in Left Atrial Volume [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
Left atrial volume is a measure of diastolic function.
Change in Plasma Triiodothyronine (T3) [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
Plasma triiodothyronine (T3) is a biological and inflammatory marker.
Change in Interleukin-6 (IL-6) [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
Interleukin-6 (IL-6) is a biological and inflammatory marker.
Change in Troponin-T [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
Troponin-T is a biological and inflammatory marker.
Change in B-type Natriuretic Peptide (BNP) [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
B-type natriuretic peptide (BNP) is a biological and inflammatory marker.
Change in High Sensitivity C-reactive Protein (hsCRP) [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
High sensitivity C-reactive protein (hsCRP) is a biological and inflammatory marker.
Change in Progression of Thoraco-abdominal Aortic Plaque Volume [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
Change from baseline to Week 48 in thoraco-abdominal aortic plaque volume.
Change in Progression of Thoraco-abdominal Aortic Wall Volume [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
Change from baseline to Week 48 in thoraco-abdominal aortic wall volume
Change in Progression of Aortic Compliance [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
Change from baseline to Week 48 in aortic compliance.
Change in Progression of Left Ventricular End-systolic Volume Index [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
Change from baseline to Week 48 in left ventricular end-systolic volume index.
Change in Progression of Left Ventricular End-diastolic Volume Index [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
Change from baseline to Week 48 in left ventricular end-diastolic volume index.
Change in Progression of Left Ventricular Ejection Fraction [ Time Frame: Baseline to 48 weeks ] [ Designated as safety issue: No ]
Change from baseline to Week 48 in left ventricular ejection fraction.

Enrollment:	227
Study Start Date:	February 2008
Study Completion Date:	March 2012
Primary Completion Date:	September 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Paricalcitol Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.	Drug: paricalcitol 2 µg capsule Other Names: ABT-358 Zemplar
Placebo Comparator: Placebo Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.	Drug: placebo placebo capsule

Detailed Description:

Patients who met the inclusion criteria and did not meet any of the exclusion criteria were randomized in a 1:1 ratio to each treatment group to receive paricalcitol capsules or placebo. A stratified randomization scheme was used to ensure balance among treatment groups with respect to country, gender, and baseline renin angiotensin-aldosterone system (RAAS) inhibitor use (yes/no).

Participants who completed the 48-Week Treatment Period could continue on in the ongoing Long-term Follow-up Period that was to last 18 months, with study visits at 6 months, 12 months and 18 months post Treatment Week 48 Visit. Participants did not receive study drug, nor were they to have undergone echocardiogram/MRI procedures during the Long-term Follow-up Period.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Estimated glomerular filtration rate (GFR) between 15-60 mL/min/1.73 m^2
Serum intact parathyroid hormone (iPTH) value between 50-300 pg/mL
Corrected serum calcium level 8.0-10.0 mg/dL (2.0-2.5 mmol/L)
Phosphorous level less than or equal to 5.2 mg/dL (1.68 mmol/L)
Serum albumin greater than or equal to 3.0 g/dL (30 g/L)
Echocardiogram results of:
- Females: Left ventricular (LV) ejection fraction greater than or equal to 50% and septal wall thickness between 11-17 mm; and,
- Males: LV ejection fraction greater than or equal to 50% and septal wall thickness between 12-18 mm
If the subject is receiving renin-angiotensin-aldosterone system (RAAS) inhibitors the dose must have been stable for greater than one month prior to the Screening Period. However, the subject may have switched to different brands but at equivalent doses as determined by the study physician during the month prior to the Screening Period.
Subject must have a technically adequate baseline cardiac magnetic resonance imaging (MRI).

Exclusion Criteria:

Subject has previously been on active vitamin D therapy within the four weeks prior to the Screening Period
Pregnant or lactating females
Subject is expected to initiate renal replacement therapy within one year
Subject is taking calcitonin, bisphosphonates, cinacalcet, glucocorticoids (except topical or inhaled glucocorticoids)
Subject had clinically significant coronary artery disease (CAD) within 3 months prior to the Screening Period, defined as either hospitalization for myocardial infarction (MI) or unstable angina; new onset angina with positive functional study or coronary angiogram revealing stenosis; or coronary revascularization procedure.
Subject had major cardiac valve abnormality linked with LVH and/or diastolic dysfunction, defined as either aortic valve area ≤ 1.5 cm^2 or a mean gradient of > 20 mmHg; or regurgitation lesions; more than moderate mitral regurgitation, or more than moderate aortic regurgitation.
Subject had asymmetric septal hypertrophy defined as septal wall thickness/posterior wall thickness ratio > 1.5 based on screening echocardiogram.
Subject had a severe cerebrovascular accident (CVA) within the last 3 months (e.g., hemorrhagic) prior to screening.
Subject had full remission from a malignancy for less than 1 year except completely excised non-melanoma skin cancer (e.g., basal or squamous carcinoma) or any history of bone metastasis.
Subject had comorbid conditions (e.g., advanced malignancy, advanced liver disease) with a life expectancy less than 1 year.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00497146

Show 71 Study Locations

Sponsors and Collaborators

AbbVie (prior sponsor, Abbott)

Massachusetts General Hospital

Investigators

Study Director:

Ann Eldred, MD

AbbVie

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided by AbbVie

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani R. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J. 2012 Dec;164(6):902-9.e2. doi: 10.1016/j.ahj.2012.09.018. Epub 2012 Oct 29.

Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012 Feb 15;307(7):674-84.

Thadhani R, Appelbaum E, Chang Y, Pritchett Y, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson T, Audhya P, Andress D, Zhang W, Ye J, Packham D, Singh B, Zehnder D, Manning WJ, Pachika A, Solomon SD. Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol. 2011;33(2):139-49. Epub 2011 Jan 18.

Thadhani R. Targeted ablation of the vitamin D 1alpha-hydroxylase gene: getting to the heart of the matter. Kidney Int. 2008 Jul;74(2):141-3.

Responsible Party:	AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:	NCT00497146 History of Changes
Other Study ID Numbers:	M10-030, 2007-001689-34
Study First Received:	July 3, 2007
Results First Received:	September 22, 2011
Last Updated:	March 8, 2013
Health Authority:	United States: Food and Drug Administration Czech Republic: State Institute for Drug Control Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Romania: National Medicines Agency Spain: Agencia Española de Medicamentos y Productos Sanitarios United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by AbbVie:

paricalcitol
Zemplar
PRIMO
Chronic Kidney Disease Stage 3B/4

Additional relevant MeSH terms:

Hypertrophy
Kidney Diseases
Renal Insufficiency
Hypertrophy, Left Ventricular
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Pathological Conditions, Anatomical
Urologic Diseases
Cardiomegaly

Heart Diseases
Cardiovascular Diseases
Ergocalciferols
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions
Vitamins
Micronutrients
Growth Substances

ClinicalTrials.gov processed this record on May 16, 2013